News
KTTAW
--
0.00%
--
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurolog...
GlobeNewswire · 04/14 20:15
We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 04/05 19:57
BRIEF-Pasithea Therapeutics Announces Financial And Business Results For The Fourth Quarter
reuters.com · 03/30 20:22
Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis ---- Launched ketamine clinics in the U.K. and U.S. and ex...
GlobeNewswire · 03/30 20:15
Pasithea Therapeutics Announces Collaboration with The Glimpse Group
- The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI BEACH, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeut...
GlobeNewswire · 03/08 13:00
EXCLUSIVE: Pasithea Therapeutics Announces Collaboration With The Glimpse Group To Co-Develop Virtual Reality Environments For Patients With Psychiatric Disorders
Miami Beach, FL / March 8, 2022 -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective
Benzinga · 03/08 12:30
BRIEF-Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK
reuters.com · 02/24 13:21
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimul...
GlobeNewswire · 02/24 13:00
BRIEF-Pasithea Therapeutics Appoints Preeminent Scientist Dr. Daniel Weinberger
reuters.com · 02/09 13:59
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger
Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illnessMIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechno...
GlobeNewswire · 02/09 13:00
Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments
In-person clinic will provide ketamine therapy and other novel mental health treatments, including repeated transcranial magnetic stimulation (“rTMS”)MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea...
GlobeNewswire · 01/26 13:00
BRIEF-Pasithea Therapeutics Corp Files For Potential Offering Of 17.7 Mln Shares Of Common Stock Offered By Selling Stockholders
reuters.com · 12/09/2021 22:50
Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurolog...
GlobeNewswire · 11/29/2021 22:45
Ault Global Holdings Founder Tweets '"Today we sold all 390,000 shares of $KTTA and 390,000 $KTTAW we owned for a very nice win" sold through our subsidiary. $DPW'
https://twitter.com/ToddAultIII/status/1463214310306430981
Benzinga · 11/23/2021 18:35
EXCLUSIVE: Pasithea Therapeutics CEO, Tiago Reis Marques Now Interviewing On Benzinga Live Tv
Click To Tune In Here... https://www.youtube.com/watch?v=FyxiHbVHAQk
Click To Tune In Here...  · 11/23/2021 16:46
BRIEF-Pasithea Therapeutics Adds Esketamine Nasal Spray To Its Clinic Offerings In The U.K.
reuters.com · 11/23/2021 13:32
Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disordersMIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA...
GlobeNewswire · 11/23/2021 13:00
EXCLUSIVE: Pasithea Therapeutics' Subsidiary Pasithea Clinics Reports It Has Been Approved To Provide Esketamine Nasal Spray (SPRAVATO) For Treatment-Resistant Depression In Adults
Miami Beach, FL / November 23, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and
Benzinga · 11/23/2021 12:30
Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
-- Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disorders -- -- First mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming months -- ...
GlobeNewswire · 11/17/2021 13:00
EXCLUSIVE: Pasithea Therapeutics' Wholly Owned Subsidiary Pasithea Clinics To Launch In-Home Intravenous Ketamine Therapy In New York City, Los Angeles, San Diego, And San Francisco To Expand Its International Footprint
Miami Beach, FL / November 17, 2021 -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and
Benzinga · 11/17/2021 12:30
Webull provides a variety of real-time KTTAW stock news. You can receive the latest news about Pasithea Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company. The Company is engaged on psychiatric and neurological research regarding central nervous system (CNS) disorders with focus on translating the research into clinic-ready drugs. The Company's secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician or medical providers to administer intravenous infusions of ketamine.